INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care. The company focuses on building, acquiring, and operating fertility clinics, including “INVO Centers” offering the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell® medical device. This device allows fertilization and early embryo development to occur in vivo within the woman’s body, providing a more natural, intimate, and affordable alternative to traditional IVF. INVO Fertility operates multiple centers in the U.S. and distributes the INVOcell technology to third-party clinics. The company separated its fertility and oncology businesses in April 2025 to focus exclusively on fertility care.

Employees - 33, CEO - Steven M. Shum, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -11.1, Piotroski Score(max is 10): 3, Working Capital: $-11063858, Total Assets: $19319239, Retained Earnings: $-90203241, EBIT: -24853536, Total Liabilities: $16687766, Revenue: $6619956

- Current Price $ - Analyst Target Price $